Drug Profile
Research programme: melanocortin receptor agonists - Competitive Technologies/XION
Latest Information Update: 15 Sep 2009
Price :
$50
*
At a glance
- Originator Competitive Technologies - XION Corporation (JV)
- Class Hormones; Peptides
- Mechanism of Action Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Obesity; Sexual function disorders
Most Recent Events
- 09 Sep 2009 Investigation in Obesity in USA (unspecified route)
- 09 Sep 2009 Investigation in Sexual function disorders in USA (unspecified route)